A Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple Myeloma

We sought a regimen that incorporates optimal novel agents in transplant-ineligible patients that balances efficacy with toxicity. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population. RVD lite was administered over a 35-day cycle. Lenalidomide 15 mg was g...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: O’Donnell, Elizabeth K., Laubach, Jacob P., Yee, Andrew J., Chen, Tianqi, Huff, Carol Ann, Basile, Frank G., Wade, Philip M., Paba-Prada, Claudia E., Ghobrial, Irene M., Schlossman, Robert L., Burke, Jill N., Harrington, Cynthia C., Lively, Kathleen J., Lyons, Hannah F., Munshi, Nikhil C., Anderson, Kenneth C., Trippa, Lorenzo, Richardson, Paul G., Raje, Noopur S.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6074026/
https://ncbi.nlm.nih.gov/pubmed/29740809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15261
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki